Immunologic Factor
rilotumumab
Definitions related to rilotumumab:
  • A fully human IgG2 monoclonal antibody directed against the human hepatocyte growth factor (HGF) with potential antineoplastic activity. Anti-HGF monoclonal antibody AMG 102 binds to and neutralizes HGF, preventing the binding of HGF to its receptor c-Met and so c-Met activation; inhibition of c-Met-mediated signal transduction may result in the induction of apoptosis in cells expressing c-Met. c-Met (HGF receptor or HGFR), a receptor tyrosine kinase overexpressed or mutated in a variety of epithelial cancer cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.
    NCI Thesaurus
    U.S. National Cancer Institute, 2021
  • A substance being studied in the treatment of cancer. It binds to a protein called hepatocyte growth factor (HGF), which may cause cancer cells to grow. Blocking this may cause cancer cells to die. AMG 102 is a type of monoclonal antibody.
    NCI Dictionary of Cancer Terms
    U.S. National Cancer Institute, 2021
Try this search on: Farlex, Merriam-Webster, Oxford Dictionary, or Wordnik

This content should not be used in place of medically-reviewed decision support reference material or professional medical advice. Some terms may have alternate or updated definitions not reflected in this set. The definitions on this page should not be considered complete or up to date.